LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

Search

Artivion Inc

Fechado

SetorSaúde

28.46 0.64

Visão Geral

Variação de preço das ações

24h

Atual

Mín

27.99

Máximo

29.08

Indicadores-chave

By Trading Economics

Rendimento

16M

-505K

Vendas

1.7M

99M

EPS

-0.394

Margem de lucro

-0.51

Funcionários

1,600

EBITDA

2.7M

2.1M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+14.52% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-172M

996M

Abertura anterior

27.82

Fecho anterior

28.46

Sentimento de Notícias

By Acuity

50%

50%

195 / 382 Ranking em Healthcare

Artivion Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de mai. de 2025, 23:59 UTC

Principais Notícias
Ganhos

Naver 1Q Net Slumps on Higher Costs

8 de mai. de 2025, 23:39 UTC

Ganhos

OCBC 1Q Net Down on Lower Interest Income

8 de mai. de 2025, 23:01 UTC

Ganhos

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 de mai. de 2025, 22:52 UTC

Ganhos

REA Expects Annual Listings Growth Despite April Decline

8 de mai. de 2025, 22:46 UTC

Ganhos

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 de mai. de 2025, 23:41 UTC

Conversa de Mercado

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 de mai. de 2025, 23:30 UTC

Ganhos

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 de mai. de 2025, 23:29 UTC

Ganhos

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 de mai. de 2025, 23:22 UTC

Ganhos

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 de mai. de 2025, 23:22 UTC

Ganhos

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 de mai. de 2025, 23:21 UTC

Ganhos

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 de mai. de 2025, 23:21 UTC

Ganhos

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 de mai. de 2025, 23:17 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 de mai. de 2025, 23:05 UTC

Conversa de Mercado

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 de mai. de 2025, 23:05 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de mai. de 2025, 23:01 UTC

Principais Notícias

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 de mai. de 2025, 22:28 UTC

Ganhos

REA Expects FY 2025 Listings Growth of 1-2%

8 de mai. de 2025, 22:28 UTC

Ganhos

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 de mai. de 2025, 22:27 UTC

Ganhos

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 de mai. de 2025, 22:27 UTC

Ganhos

REA Says April Residential Listings Fell by 11% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 de mai. de 2025, 22:26 UTC

Ganhos

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 de mai. de 2025, 22:25 UTC

Ganhos

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 de mai. de 2025, 22:25 UTC

Ganhos

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparação entre Pares

Variação de preço

Artivion Inc Previsão

Preço-alvo

By TipRanks

14.52% parte superior

Previsão para 12 meses

Média 32.5 USD  14.52%

Máximo 35 USD

Mínimo 30 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Artivion Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

195 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.